James Waldron

Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to go some way toward alleviating investors' concerns with its ulcerative colitis prospect.

Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.

A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed that this change has formed part of a round of 103 layoffs.

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.

Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech's rheumatoid arthritis (RA) drug as the ideal fit for its own expertise.

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs involved flunk clinical trials.

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study.

Hansoh Pharmaceutical's pair of much-hyped ADCs continue to justify partner GSK's decision to elevate them to “priority asset” status.

Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision.

Pharma platform company China Medical System Holdings (CMS) has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collaboration aimed at a “mass-market” central nervous system (CNS) indication.